Asia Pacific Science Press

Asia Pacific Journal of Clinical Medical Research
ISSN(O):3079-8345
ISSN(P):3079-8337
Vol. 1 No.6 (2025)

Study on the Application and Time-Dependent Effects of Antibiotics in the Treatment of Neonatal Pneumonia

Zhao Lu*

The Fifth Clinical School of Capital Medical University, Beijing, 100000, China

Corresponding author: Zhao Lu, luzhao@mail.ccmu.edu.cn

Abstract: This article first outlines the fundamental definitions of Mycoplasma pneumoniae and the basic principles of antibiotics. It then analyzes and discusses the progress in antibiotic application and time-effect studies for neonatal pneumonia treatment, specifically comparing conventional antibiotic therapy with stepwise treatment regimens, and contrasting monotherapy with penicillin, monotherapy with cephalosporins, and combination therapy. Finally, it offers a prospective outlook on antibiotic application and time-effect research in neonatal pneumonia treatment, aiming to provide valuable reference for further scholarly investigations.

Keywords: Neonatal Pneumonia; Antibiotics; Clinical Application; Time-Dependent Effects; Research Progress; Future Outlook

Published: Dec 31, 2025

DOI: https://doi.org/10.62177/apjcmr.v1i6.1016

Introduction:

Neonatal pneumonia primarily arises when infants inhale amniotic fluid, meconium, or other foreign substances during intrauterine development, delivery, or the postpartum period, leading to pulmonary infection. Additionally, neonatal exposure to pathogenic microorganisms during delivery or neonatal care can also trigger pneumonia. Typically, affected infants exhibit clinical symptoms such as rapid breathing, severe coughing, and fever, which directly compromise the respiratory system. As blood oxygen saturation levels decline, the condition may become life-threatening. Antibiotic therapy is the primary treatment for neonatal pneumonia. Specific antibiotics are used to achieve bactericidal and bacteriostatic effects, preventing the spread of pulmonary inflammation. Once the inflammation is adequately controlled, clinical symptoms like coughing, fever, and rapid breathing subside, thereby ensuring the infant's safety. To understand the current state of clinical research on neonatal pneumonia treatment, this article analyzes and discusses the application of antibiotics in neonatal pneumonia therapy and advances in time-effect studies. It aims to provide valuable references for related research topics. Detailed content is presented below.

1.Overview of Mycoplasma pneumoniae

Mycoplasma pneumoniae is an independent microorganism lacking a cell wall. Commonly used clinical antibiotics such as cephalosporins and penicillins are ineffective against Mycoplasma pneumoniae infections. Extensive clinical research indicates that Mycoplasma pneumoniae exhibits relatively high susceptibility to quinolone antibiotics with low resistance rates, whereas its susceptibility to macrolides is relatively low with higher resistance rates. However, quinolones may

adversely affect the physical development of infants and young children, precluding their use. Clinically, macrolides are primarily employed for treating neonatal pneumonia. The efficacy of azithromycin, for instance, has gained widespread recognition among physicians, demonstrating macrolides' strong clinical effectiveness against mycoplasma pneumonia [1].

2.Fundamental Principles of Antibiotics

Antibiotics refer to metabolic products generated by higher plants and microorganisms during natural survival processes, exhibiting pathogenic resistance or related activities. These substances effectively inhibit the proliferation of specific pathogenic microorganisms, preventing their excessive multiplication and subsequent damage to host cells. Analysis of antibiotic mechanisms reveals that clinical applications inhibit pathogen proliferation through multiple pathways: suppressing nucleic acid transcription and replication, inhibiting protein synthesis, disrupting bacterial cell wall formation, and altering cell membrane permeability. These actions shorten pathogen survival time to achieve therapeutic outcomes.

For instance, two commonly used antibiotics in clinical practice are penicillin and cephalosporin. Penicillin is primarily extracted from Penicillium fungi. When used clinically, it effectively disrupts bacterial structural components and inhibits bacterial cell wall synthesis, thereby achieving the desired therapeutic effects of sterilization and inflammation reduction. Cephalosporins are derived from natural cephalosporin C, obtained through the cultivation of Cephalosporium coronatum, which undergoes semi-synthetic modification to produce cephalosporins. These drugs exhibit a relatively broad spectrum of antibacterial activity. In clinical applications, cephalosporins also inhibit bacterial growth by disrupting cell wall synthesis [2].

Comparing the two classes, penicillins exhibit a relatively higher incidence of allergic reactions in clinical use. However, regardless of the antibiotic chosen, physicians must avoid overuse. Patient misuse of antibiotics may lead to the emergence of drug-resistant bacteria, diminishing the clinical efficacy of both penicillins and cephalosporins and compromising effective disease control.

3.Advances in Antibiotic Application and Time-Dependent Effects in Neonatal Pneumonia Treatment

3.1 Comparative Study of Conventional Antibiotic Therapy vs. Stepwise Treatment Regimens

In her study [3], Jin Jiani administered conventional antibiotic therapy to the control group and a stepwise antibiotic regimen to the observation group. Comparing key indicators between groups—including overall clinical response rates, symptom resolution, serum parameter changes, and adverse antibiotic treatment incidence—revealed significantly superior recovery outcomes in the observation group ($P < 0.05$).

The study concluded that in treating neonatal pneumonia, stepwise antibiotic therapy allows timely adjustment of antibiotic dosage based on the patient's condition at appropriate stages. This approach achieves optimal therapeutic outcomes—such as shortening recovery time and reducing adverse drug reactions—while maintaining safety and reliability. Analysis of this study demonstrates strict adherence to medical research regulations, obtained informed consent from parents of newborn pneumonia patients, and was conducted under the supervision of the hospital's Medical Ethics Committee. These measures ensured scientific rigor, lending high credibility to the research conclusions.

3.2 Comparative Study of Monotherapy with Penicillin, Monotherapy with Cephalosporin, and Combination Therapy

In conducting related research [4],statistically analyzed antibiotic usage in 90 pediatric pneumonia cases, documenting treatment data for ceftriaxone, cefazolin sodium, cefazolin sodium, penicillin, cefuroxime with penicillin, cefazolin sodium with penicillin, and cefazolin with penicillin. The investigation revealed that current neonatal pneumonia treatment primarily involves monotherapy with penicillin, monotherapy with cephalosporins, or combination therapy (penicillin and cephalosporins). Among these, combination therapy was administered to the largest number of patients, followed by monotherapy with penicillin.

Post-treatment analysis revealed that infants receiving combination therapy exhibited the highest incidence of complications. This clearly indicates that due to the immature development of neonatal organs, the combined use of penicillin and cephalosporin drugs poses significant health risks to infants, directly manifested as elevated complication rates. Additionally,

combination therapy is more complex, as physicians must precisely control the ratios and dosages of combined medications to avoid adversely affecting the child's health. Given the higher incidence of complications in children receiving combination therapy, their recovery periods were prolonged, resulting in overall poor clinical outcomes for this regimen.

Comparing data from children treated with either monotherapy penicillin or monotherapy cephalosporin reveals that those receiving penicillin monotherapy achieved clinical recovery in a relatively shorter timeframe than those on cephalosporin monotherapy. This indicates that the clinical efficacy of monotherapy with cephalosporins is inferior to that of monotherapy with penicillin. However, when comparing the two regimens, the incidence of complications was relatively lower in children treated with monotherapy cephalosporins. This indicates that following a multidisciplinary consultation for neonatal pneumonia, if the infant's condition is deemed not severely critical, monotherapy with cephalosporins may be selected to prevent complications. When the infant's condition is relatively severe, clinicians should adopt monotherapy with penicillin to ensure antibiotics rapidly suppress the proliferation of pathogenic microorganisms within the infant's body, preventing deterioration of the condition that could threaten the infant's life.

3.3 Comparative Analysis of Antibiotic Application and Time-Effect Research Findings in Neonatal Pneumonia Treatment

Comparing the findings of Sun Zhicui and Jin Jiani reveals apparent contradictions: Sun's study indicates monotherapy outperforms combination therapy, while Jin's research shows stepwise antibiotic therapy surpasses conventional monotherapy. While these conclusions appear contradictory at first glance, deeper analysis reveals no conflict. Combination therapy involves pairing antibiotics with cephalosporins, whereas stepwise antibiotic therapy allows physicians to dynamically adjust treatment regimens based on real-time monitoring of the infant's condition. This approach ensures more rational antibiotic use and better disease control. Thus, in treating neonatal pneumonia, the optimal approach for antibiotic administration is to adjust the regimen based on the infant's real-time condition changes. This eliminates the negative effects of monotherapy and ensures effective control of the infant's condition.

4.Future Research Directions on Antibiotic Application and Time-Dependent Effects in Neonatal Pneumonia Treatment

Future research in this area should not only delve into the clinical efficacy of antibiotics to identify more effective treatment regimens but also standardize and regulate antibiotic protocols—including dosage and administration procedures. This will enhance the reference value of research findings and facilitate the transfer of relevant experience into clinical practice. Furthermore, to reduce mortality rates in neonatal pneumonia treatment, major hospitals should enhance communication and collaboration. Organizing specialized conferences to share research insights and clinical experience will consolidate medical resources, ensuring optimal care for every case of neonatal pneumonia and safeguarding the health and lives of affected infants.

Conclusion

In summary, this article focuses on antibiotic application and time-effect studies in neonatal pneumonia treatment, discussing current research progress. By examining research findings alongside actual clinical treatment practices, it outlines prospects for future research. Given the unique nature of neonatal pneumonia, the research and outlook presented herein represent only the author's humble perspective. To facilitate more systematic investigation and discussion, a rigorous thematic plan should be organized. This plan should examine the current state of research both domestically and internationally, systematize cutting-edge findings and clinical challenges, thereby clarifying future research directions. Such efforts will better address practical clinical issues in neonatal pneumonia treatment and enable the translation of relevant research outcomes into clinical practice protocols.

Funding

No

Conflict of Interests

The authors declare that there is no conflict of interest regarding the publication of this paper.

Reference

[1] Yang, X. (2025). Clinical value of combined acetylcysteine and budesonide nebulization therapy in neonatal pneumonia. Chinese Science & Technology Journal Database (Abstract Edition): Medicine & Health, (5), 037–040.

[2] Chen, H. R. (2025). Effect of cefotaxime injection combined with ambroxol injection and budesonide nebulization on neonatal pneumonia and its impact on inflammatory factor levels. Chinese Science & Technology Journal Database: Medicine, (5), 029–032.

[3] Jin, J. N., & Wu, X. Y. (2021). Analysis of the application value of antibiotics in treating neonatal pneumonia and their impact on recovery time. Systematic Medicine, 6(15), 89–91.

[4] Sun, Z. C. (2021). Clinical application and time-effect analysis of antibiotics in the treatment of neonatal pneumonia. Smart Health, 7(7), 148–150.